Bilateral Avascular Necrosis of the Hips in a Patient With Sickle Cell Trait and Chronic Alcohol Use [0.03%]
sickle细胞病 trait和慢性饮酒引起的双侧股骨头无血管坏死
Sarah Al-Zaher,Janan Niknam,Sivarama K Kotikalapudi
Sarah Al-Zaher
Sickle cell trait (SCT) is generally considered a benign carrier state, unlike sickle cell disease (SCD), which is frequently associated with complications such as avascular necrosis (AVN). While AVN affects approximately 30% of patients wi...
Case Reports
Journal of hematology. 2025 Oct 10;14(5):262-266. DOI:10.14740/jh2084 2025
Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program [0.03%]
重度甲型血友病患者使用emicizumab的临床和患者转归指标：在标准化项目中的评估结果分析
Ingrid Blydt-Hansen,Michelle Bech,Shannon Jackson
Ingrid Blydt-Hansen
Background: Emicizumab (Hemlibra) became more accessible for Canadians in 2021, when Canadian Blood Services approved it under formulary for prophylaxis in patients with severe hemophilia A (PWHA) without inhibitors. This...
Hala Alsoukhni,Dima Al-Dabbas,Mohammad Masalha et al.
Hala Alsoukhni et al.
Acute undifferentiated leukemia (AUL) is a rare, aggressive type of acute leukemia associated with poor prognosis, in which the blasts lack lineage commitment to either the myeloid or lymphoid lineages. It is classified according to the Wor...
Case Reports
Journal of hematology. 2025 Oct 10;14(5):267-272. DOI:10.14740/jh2090 2025
Iron-Induced Hypophosphatemia: A Review of Pathophysiology, Drug Safety, and Pharmacogenomic Perspectives [0.03%]
铁诱导的低磷血症：病理生理、药物安全和药理基因组学视角综述
Simone Pozzessere
Simone Pozzessere
Intravenous (IV) iron therapy is a cornerstone in the management of iron deficiency anemia, yet its administration is associated with significant side effects, most notably hypophosphatemia. This adverse event is not a class effect but is d...
Fever: Harmless Heat or a Deadly Inferno? Unmasking Hemophagocytic Lymphohistiocytosis and Beyond: A Rare Case of Mast Cell Sarcoma and Overview of HLH [0.03%]
发热：无害的热度还是致命的烈焰？——以一例巨噬细胞活化综合征伴嗜酸性肉芽肿和不明系统性肿瘤为视角揭露噬血细胞综合征及其他
Karan J Yagnik,Adelaine Espiritu,Malay Rathod et al.
Karan J Yagnik et al.
Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal hyperinflammatory syndrome characterized by uncontrolled activation of the immune system, often secondary to infections, autoimmune diseases, or malignancies. While ma...
Case Reports
Journal of hematology. 2025 Oct 10;14(5):273-280. DOI:10.14740/jh2087 2025
Novel Agents and Immunotherapies for Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System: Innovating for Impact in a Disease With Unmet Needs [0.03%]
中枢神经系统原发性弥漫大B细胞淋巴瘤的新型药物和免疫疗法：创新改善一种未被满足需求疾病的结局
Tatyana Gavrilova
Tatyana Gavrilova
Primary diffuse large B-cell lymphoma of the central nervous system (CNS-DLBCL), the most prevalent subtype of primary CNS lymphoma (PCNSL), is a highly aggressive extranodal non-Hodgkin lymphoma (NHL) that arises in the brain, spinal cord,...
Osama Batayneh,Deevyashali Parekh,Margarita Vazquez Almonte et al.
Osama Batayneh et al.
Background: While molecular and cytogenetic testing may change prognosis and guide treatment intensity for patients with acute myeloid leukemia (AML), timing from diagnosis to treatment (TDT) on the other hand may impact ...
Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Reversal of Anticoagulation: Evaluation of Efficacy, Safety, and Cost Savings [0.03%]
Amer Al Homssi,Ryan Lokkesmoe,Ryan Powers et al.
Amer Al Homssi et al.
Background: Four-factor prothrombin complex concentrate (4F-PCC) is used for warfarin reversal and off-label management of bleeding in patients taking direct oral anticoagulants (DOACs). Dosing strategies that optimize he...
Rowena Lee Ying Kwan,Ryan Mao Heng Lim,Jason Yongsheng Chan
Rowena Lee Ying Kwan
Background: Ocular adnexal marginal zone lymphoma (OAMZL) is the most common subtype of primary ocular lymphoma and has been rising in incidence in Asian populations. ...
Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management [0.03%]
Muralidhar Idamakanti,Ala Ebaid,Rani Indrani Bijjam et al.
Muralidhar Idamakanti et al.
Mast cell leukemia (MCL) is an exceedingly rare and aggressive variant of systemic mastocytosis (SM). MCL is classified as primary, occurring de novo without prior mast cell (MC) disorders or secondary, from a pre-existing SM, and acute agg...